{"article_id": "A_q3_2021.txt", "article": ["core revenue growth excludes the impact of currency and the acquisitions and divestitures completed within the past 12 months .", "q3 revenue of $ 1.59 billion is up a reported 26 % and is up 21 % core .", "this is against the mass decline of 3 % in q3 of last year , so we are well above fiscal year 2019 pre-pandemic levels .", "our q3 operating margin is 26 % , this is up 230 basis points from last year .", "eps is $ 1.10 , up 41 % year - over - year .", "we continue to perform extremely well in pharma , our largest market growing 27 % with strength in both small and large molecule segments .", "our large molecule business grew roughly 52 % in the quarter and now represents 36 % of our overall pharma revenue , up from the mid 20s just a few years ago .", "in chemical energy , our business is recovering faster than expected , expanding 23 % in the quarter .", "looking at our performance by business unit , the life sciences and applied markets group generated revenue of $ 680 million .", "lsag is up 22 % on a reported basis , this is up 18 % core , off just a 4 % decline last year .", "our performance is led by strength in pharma , which is up 22 % and chemical energy up 31 % .", "all businesses delivered strong growth led by cell analysis at 38 % growth and our lc and lcms businesses , which grew 22 % .", "the agilent crosslab group posted revenue of $ 560 million , this is up a reported 21 % and up 15 % on a core basis .", "these results are on top of 1 % growth last year .", "all end markets grew mid teens or higher with the exception of environmental and forensics , but still grew 9 % .", "the diagnostics and genomics group produced revenue of $ 346 million , up 44 % reported and up 37 % core , compared to an 8 % decline last year .", "the quarterly results exceeded our expectations , easily surpassing the $ 30 million revenue milestone , while one quarter does not make a trend , our team has done a tremendous job increasing the output in a high quality manner .", "this gives us increased confidence in our ability to exceed the $ 200 million annual run rate of revenue with existing capacity .", "while still less than 10 % of dgg revenue , our china business grew 50 % in the quarter .", "revenue was $ 1.59 billion , reflecting reported growth of 26 % , core revenue growth was 21 % .", "currency added 4.5 % for the quarter and m&a added 0.5 point .", "our largest market pharma grew 27 % during the quarter , after growing 2 % last year .", "the performance was led by the continued strength in our large molecule business growing 52 % , while our small molecule business grew mid teens , and all regions in the pharma market grew double - digits .", "chemical and energy also performed well this quarter with 23 % growth .", "even after accounting for the comparison against the 10 % decline last year , this was clearly our best quarter since the onset of the pandemic .", "the diagnostics and clinical market grew 28 % against the decline of 10 % a year ago , our softest quarter last year .", "on a regional basis , all regions grew with china up 41 % and americas delivering 38 % growth .", "in the academia and government market , we delivered 12 % growth as most research labs continue to open globally and expand capacity .", "the food market continued its double - digit performance growing 12 % on top of growing 1 % last year .", "rounding out our key markets , environmental and forensics came in with 5 % growth .", "on a geographic basis , all regions demonstrated solid growth led by the americas at 32 % and europe at 23 % , both exceeding our expectations .", "and as expected , china was up 8 % on top of 11 % growth last year .", "now turning to the rest of the p&l , third - quarter gross margin was 55.9 % , up 80 basis points from a year ago despite roughly 40 basis points of headwind from currency .", "gross margin improvement -- performance along with continued operating expense leverage resulted in operating margin for the third quarter of 26 % , improving 230 basis points over last year .", "putting it all together , we delivered earnings per share of $ 1.10 , up 41 % versus last year .", "our tax rate was 14.75 % and share count was 306 million shares , as expected .", "we delivered $ 334 million in operating cash flow during the quarter , showing a strong conversion from net income and up more than 15 % from last year while crossing the $ 1 billion mark in nine months .", "during the quarter , we returned $ 172 million to our shareholders , paying out $ 59 million in dividends and repurchasing roughly 800,000 shares for $ 113 million .", "year - to - date , we 've returned $ 829 million to shareholders in the forms of dividends and share repurchases .", "and we ended the quarter with $ 1.4 billion in cash , $ 2.9 billion in outstanding debt and a net leverage ratio of 0.8 .", "we are increasing our full - year revenue projection to a range of $ 6.29 billion to $ 6.32 billion , up $ 125 million at the midpoint from previous guidance and representing reported growth of 17.8 % to 18.4 % and core growth of 14.5 % to 15 % .", "in addition , we are on track to deliver roughly $ 100 million in covid - related revenue in fiscal 2021 , in line with our expectations from the beginning of the year and flat to last year .", "we expect to continue our strong operating leverage , and so we are increasing our fiscal 2021 non-gaap earnings per share to a range of $ 4.28 to $ 4.31 per share , up 30 % to 31 % for the year .", "this translates the fourth quarter revenue ranging from $ 1.63 billion to $ 1.66 billion .", "this represents reported growth of 10 % to 12 % and core growth of 8.5 % to 10 % on top of the 6 % growth in q4 of last year when we started to see early signs of recovery from the strict lockdowns .", "so , our core growth excluding covid would be comparable to 9.5 % to 11 % .", "we are forecasting higher expenses in the fourth quarter as we invest to maintain our strong momentum , but expect continued operating leverage in excess of 100 basis points .", "non-gaap earnings per share is expected to be between $ 1.15 and $ 1.18 with growth of 17 % to 20 % ."], "summary_gold": "agilent technologies q3 adj earnings per share $ 1.10 .<q>q3 non -gaap earnings per share $ 1.10 .<q>sees q4 revenue $ 1.63 billion to $ 1.66 billion .<q>sees fy revenue $ 6.29 billion to $ 6.32 billion .<q>q3 revenue $ 1.59 billion versus refinitiv ibes estimate of $ 1.54 billion .<q>sees fy non -gaap earnings per share $ 4.28 to $ 4.31 .<q>sees q4 non -gaap earnings per share $ 1.15 to $ 1.18 .", "summary_pred": "in the academia and government market , we delivered 12 % growth as most research labs continue to open globally and expand capacity .<q>and we ended the quarter with $ 1.4 billion in cash , $ 2.9 billion in outstanding debt and a net leverage ratio of 0.8 .<q>revenue was $ 1.59 billion , reflecting reported growth of 26 % , core revenue growth was 21 % .<q>and as expected , china was up 8 % on top of 11 % growth last year .<q>now turning to the rest of the p&l , third - quarter gross margin was 55.9 % , up 80 basis points from a year ago despite roughly 40 basis points of headwind from currency .<q>on a geographic basis , all regions demonstrated solid growth led by the americas at 32 % and europe at 23 % , both exceeding our expectations .<q>we continue to perform extremely well in pharma , our largest market growing 27 % with strength in both small and large molecule segments .<q>rounding out our key markets , environmental and forensics came in with 5 % growth .<q>eps is $ 1.10 , up 41 % year - over - year .<q>our large molecule business grew roughly 52 % in the quarter and now represents 36 % of our overall pharma revenue , up from the mid 20s just a few years ago .<q>the agilent crosslab group posted revenue of $ 560 million , this is up a reported 21 % and up 15 % on a core basis .<q>this gives us increased confidence in our ability to exceed the $ 200 million annual run rate of revenue with existing capacity .<q>this is against the mass decline of 3 % in q3 of last year , so we are well above fiscal year 2019 pre-pandemic levels .<q>the quarterly results exceeded our expectations , easily surpassing the $ 30 million revenue milestone , while one quarter does not make a trend , our team has done a tremendous job increasing the output in a high quality manner .<q>our tax rate was 14.75 % and share count was 306 million shares , as expected .<q>this translates the fourth quarter revenue ranging from $ 1.63 billion to $ 1.66 billion .", "len_article": 48, "len_summary_gold": 7, "len_summary_pred": 16, "len_sent_scores": 48}